MARKET

EPZM

EPZM

Epizyme
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.63
-0.13
-1.92%
After Hours: 6.63 0 0.00% 16:00 07/30 EDT
OPEN
6.68
PREV CLOSE
6.76
HIGH
6.89
LOW
6.60
VOLUME
448.64K
TURNOVER
--
52 WEEK HIGH
14.56
52 WEEK LOW
6.49
MARKET CAP
676.10M
P/E (TTM)
-2.6812
1D
5D
1M
3M
1Y
5Y
Here is What Hedge Funds Think About Epizyme Inc (EPZM)
As we already know from media reports and hedge fund investor letters, hedge funds delivered their best returns in a decade. Most investors who decided to stick with hedge funds after a rough 2018 recouped their losses by the end of the fourth quarter of 2...
Insider Monkey · 2d ago
Analysts Estimate Epizyme (EPZM) to Report a Decline in Earnings: What to Look Out for
Zacks.com · 3d ago
The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26)
Benzinga · 3d ago
Biotech M&A may heat up with potential targets Horizon Therapeutics, Arrowhead Pharma, analyst says
janiecbros/E+ via Getty Images Biotech M&A is poised to heat up again as shares of the SPDR S&P Biotech’s (XBI) have fallen about 25% from their February highs, according to
Seekingalpha · 07/11 13:00
Turning Point Therapeutics Names Tombesi as Finance Chief
marketwatch.com · 06/29 13:13
BRIEF-Epizyme Says CFO Paolo Tombesi Notified That He Will Be Leaving Company
reuters.com · 06/28 21:43
Epizyme, Inc. (NASDAQ:EPZM) Insiders Increased Their Holdings
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...
Simply Wall St. · 06/28 08:15
Arcus Bio ranks in top weekly healthcare gainers amid positive domvanalimab data; Biogen hit by Lilly donanemab Breakthrough Therapy tag
JuSun/iStock via Getty Images During the week ended June 25, 2021, Healthcare sector rose 2.01% and Healthcare Select Sector SPDR ETF (XLV) gained 1.58% compared to weekly gain of 2.82% of S&P 500 ETF. Leading the
Seekingalpha · 06/28 06:31
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of EPZM. Analyze the recent business situations of Epizyme through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average EPZM stock price target is 18.63 with a high estimate of 36.00 and a low estimate of 9.00.
EPS
Institutional Holdings
Institutions: 233
Institutional Holdings: 105.17M
% Owned: 103.13%
Shares Outstanding: 101.98M
TypeInstitutionsShares
Increased
51
4.95M
New
18
1.77M
Decreased
42
8.89M
Sold Out
14
431.78K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.28%
Pharmaceuticals & Medical Research
-0.32%
Key Executives
Non-Executive Chairman/Independent Director
David Mott
President/Chief Executive Officer/Director
Robert Bazemore
Chief Financial Officer
Paolo Tombesi
Executive Vice President
Shefali Agarwal
Chief Financial Officer/Executive Vice President
Matthew Ros
Chief Scientific Officer
Jeffery Kutok
Other
Vicki Vakiener
Director
Michael Giordano
Director
Pablo Legorreta
Independent Director
Andrew Allen
Independent Director
Kenneth Bate
Independent Director
Grant Bogle
Independent Director
Kevin Conroy
Independent Director
Carl Goldfischer
Independent Director
Victoria Richon
No Data
About EPZM
Epizyme, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs). The Company develops small molecule inhibitors of other chromatin modifying proteins (CMPs). The Company's lead product candidate, tazemetostat, is a potent and selective inhibitor of the enhancer of zeste homolog 2 (EZH2) histone methyltransferases (HMT), an enzyme that plays an important role in various cancers. The Company is evaluating tazemetostat in a Phase II study in adults with relapsed or refractory non-Hodgkin lymphoma (NHL), and one Phase I study in children with molecularly defined solid tumors. The Company owns the global development and commercialization rights to tazemetostat outside of Japan.

Webull offers kinds of Epizyme Inc stock information, including NASDAQ:EPZM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EPZM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EPZM stock methods without spending real money on the virtual paper trading platform.